Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
0(0%)
Results Posted
100%(5 trials)
Terminated
2(29%)

Phase Distribution

Ph phase_1
3
43%
Ph phase_2
4
57%

Phase Distribution

3

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
4(57.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(5)
Terminated(2)

Detailed Status

Completed5
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
71.4%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (42.9%)
Phase 24 (57.1%)

Trials by Status

completed571%
terminated229%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_2

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

NCT03203642
completedphase_1

A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

NCT01559363
terminatedphase_2

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

NCT02616055
completedphase_1

A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

NCT03096080
terminatedphase_1

Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

NCT02154529
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03203642Phase 2

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

Completed
NCT01559363Phase 1

A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

Completed
NCT02616055Phase 2

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

Terminated
NCT03096080Phase 1

A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Completed
NCT02154529Phase 1

Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Terminated
NCT02616393Phase 2

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Completed
NCT02844439Phase 2

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7